Previous research overstated the generalizability of the Exenatide Study of Cardiovascular Event Lowering trial results by omitting the restriction on the percentage of patients without a prior cardiovascular event.
Am J Manag Care. 2019;25(4):170-171Takeaway Points
Cardiovascular outcome trials (CVOTs) that examine glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often include patients at high risk of cardiovascular disease. Subsequently, the results of these trials may not be generalizable to the overall type 2 diabetes (T2D) population. Recent research has compared the generalizability of several CVOTs of GLP-1 RAs.
I read with great interest the article published in an April 2018 supplement titled “Generalizability of Glucagon-Like Peptide-1 Receptor Agonist Cardiovascular Outcome Trials Enrollment Criteria to the US Type 2 Diabetes Population” by Wittbrodt et al.1 Although the authors made an important contribution to the literature by examining the generalizability of cardiovascular (CV) outcome trials to the population of US adults with type 2 diabetes (T2D), I believe that their analysis contains an important omission. Specifically, the authors state that the Exenatide Study of Cardiovascular Event Lowering (EXSCEL) trial contains no eligibility criteria regarding CV events.1 However, although patients with any level of CV risk may be enrolled, the original protocol clearly states that “recruitment will be constrained such that 40% will not have had a prior CV event and 60% will have had a prior CV event…”2 This requirement was subsequently made more restrictive in the protocol amendment, which modified the inclusion and exclusion criteria such that “…approximately 30% will not have had a prior CV event and 70% will have had a prior event.”2 An examination of the characteristics of patients who actually enrolled in the trial revealed that this more restrictive requirement was used, with 73% of patients enrolled in EXSCEL having a prior CV event.3 Although the EXSCEL trial did include patients both with and without prior CV events, it is not true that the study had no eligibility requirement regarding CV events.
An examination of the 2013-2014 National Health and Nutrition Examination Survey (NHANES) data4 revealed that this omission has a significant impact on the findings presented in the authors’ research. Specifically, a replication of the Wittbrodt et al1 examination of the EXSCEL trial revealed that, ignoring the CV enrollment criteria, 50.5% of patients with T2D would be eligible for inclusion in the EXSCEL study (Table1,5,6 [part A and part B]). This number is similar to the finding of the authors, using NHANES data from 2009-2010 and 2011-2012, which found that 47.2% of adults with T2D would be eligible for EXSCEL. However, within this 50.5% sample of individuals who fit the eligibility requirements examined by Wittbrodt et al, just 10.7% had a prior CV event (Table1,5,6). When also incorporating the recruitment criteria that 60% of patients should have had a prior CV event, the 50.5% of potentially eligible patients is reduced to 17.9%. If, alternatively, one examines the amended protocol requirement that 70% of patients had a prior CV event, the proportion of eligible patients would be reduced to 15.3%. These results suggest that by omitting the CV inclusion criteria of the EXSCEL study, the authors have included an oversampling of patients with no prior CV event relative to the stated criteria of the EXSCEL trial. As such, the analysis substantially overstates the generalizability of EXSCEL to the overall US T2D population.Author Affiliation: HealthMetrics Outcomes Research, Bonita Springs, FL.
Source of Funding: None.
Author Disclosures: Dr Lage is a consultant for pharmaceutical companies and has conducted analyses for Eli Lilly and Company, which manufactures one of the drugs discussed in the original article by Wittbrodt et al. She received no compensation for this research.
Authorship Information: Concept and design; acquisition of data; analysis and interpretation of data; drafting of the manuscript; critical revision of the manuscript for important intellectual content; and statistical analysis.
Address Correspondence to: Maureen J. Lage, PhD, HealthMetrics Outcomes Research, 27576 River Reach Dr, Bonita Springs, FL 34134. Email: firstname.lastname@example.org.REFERENCES
1. Wittbrodt ET, Eudicone JM, Bell KF, Enhoffer DM, Latham K, Green JB. Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials enrollment criteria to the US type 2 diabetes population. Am J Manag Care. 2018;24(suppl 8):S146-S155.
2. Holman RR, Bethel MA, Mentz RJ, et al; EXSCEL Study Group. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377(13):1228-1239. doi: 10.1056/NEJMoa1612917.
3. Mentz RJ, Bethel MA, Gustavson S, et al. Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). Am Heart J. 2017;187:1-9. doi: 10.1016/j.ahj.2017.02.005.
4. National Health and Nutrition Examination Survey: NHANES questionnaires, datasets, and related documentation. CDC National Center for Health Statistics website. wwwn.cdc.gov/nchs/nhanes/Default.aspx. Accessed June 1, 2018.
5. Florkowski CM, Chew-Harris JS. Methods of estimating GFR: different equations including CKD-EPI. Clin Biochem Rev. 2011;32(2):75-79.
6. James S, Angiolillo DJ, Cornel JH, et al; PLATO Study Group. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J. 2010;31(24):3006-3016. doi: 10.1093/eurheartj/ehq325.